DUBLIN, Feb. 19, 2016 /PRNewswire/ -- Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), announced that a number of key public facing corporate functions will be relocated to Ireland as part of the Company's focused international growth strategy and global expansion. This announcement furthers the Company's previously announced actions on October 22, 2015 to maximize efficiency and continue leveraging the strength of Perrigo's global platform. A number of positions will also be added to the Company's Dublin headquarters across a range of corporate functions including supply chain/global operations, procurement, enterprise risk management and corporate finance and information technology.
Perrigo has long identified Ireland as a gateway for its expansion into Europe. The acquisition of Omega Pharma in 2015, which added a pan-European branded consumer healthcare platform, the transfer of major corporate functions to Ireland, and the expansion of the Company's headquarters underscores Perrigo's commitment to European and international growth.
Global Investor Relations
As part of this expansion, Arthur Shannon will relocate to Ireland and assume the role of Vice President, Global Corporate Affairs and European Investor Relations. In this role Mr. Shannon will continue to oversee both internal and external Global Communications and will continue to be the lead point of contact for media. In addition, he will now be responsible for establishing a global government relations base from Dublin and expanding Perrigo's already robust, shareholder focused Investor Relations programs across Europe. Mr. Shannon will be moving to Dublin in early April. At that time we will update his contact information.
Separately, Bradley Joseph has been promoted to the role of Vice President, Global Investor Relations. Mr. Joseph will lead the investor relations team in designing and executing the relevant strategies, communications and investor outreach programs for the globe. He will continue to be based in Allegan, Michigan.
In addition, Lou Cherico, Vice President, Corporate Treasurer, will relocate to Dublin, to accelerate the buildout of Perrigo's Global Treasury and Risk Management functions in Ireland to better support our international expansion.
Msr. Shannon, Joseph and Cherico will report directly to Judy Brown, Executive Vice President and Chief Financial Officer at Perrigo.
Joe Papa, Chairman and CEO of Perrigo commented: "We are delighted to announce the addition of these key external facing corporate functions to our Dublin base, reinforcing our plans to expand our footprint in Ireland. These additions build on the outstanding Dublin based team currently in place. We are excited about this next chapter in our international growth. The enhancement of our Irish operations furthers the benefits of our global platform and will enable us to drive continued strong profit growth and enhance shareholder value."
Perrigo Company plc is a top five global over-the-counter ("OTC") consumer goods and leading specialty pharmaceutical company, offering patients and customers high- quality products at affordable prices. From the Company's beginning in 1887 as a packager of home remedies, it has grown to become the world's largest manufacturer of OTC healthcare products and supplier of infant formulas for the store brand market. The Company is also a leading provider of generic extended topical prescription products, and it receives royalties from sales of the multiple sclerosis drug Tysabri®. The Company provides "Quality Affordable Healthcare Products®" across a wide variety of product categories and geographies, primarily in North America, Europe and Australia, as well as in other markets, including Israel and China. Visit Perrigo online at (http://www.perrigo.com).
Logo - http://photos.prnewswire.com/prnh/20120301/DE62255LOGO
SOURCE Perrigo Company plc
For further information: Bradley Joseph, Vice President, Global Investor Relations and Communications, (269) 686-3373, E-mail: firstname.lastname@example.org; Arthur J. Shannon, Vice President, Global Corporate Affairs and European Investor Relations, (269) 686-1709, E-mail: email@example.com